Last reviewed 2026-04-20 · How we verify

Nicoclonol (NICOCLONATE)

Phase 2 active Small molecule

Nicoclonol (generic name: NICOCLONATE) is a nicoclonate drug. It is currently in Phase 2 development.

Nicoclonate is a small molecule that works by interacting with a specific target in the body, but the exact mechanism is unknown.

Nicoclonate is a small molecule drug in the nicoclonate class, but information on its target and mechanism of action is not available. Its commercial status and approved indications are also unknown. As a result, there is limited information available on this compound. Further research is needed to understand its potential therapeutic applications and safety profile. Due to the lack of available data, it is difficult to provide a comprehensive summary of Nicoclonate.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NICOCLONATE
Drug class	nicoclonate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, we don't have enough information to explain how Nicoclonate works in simple terms. However, in general, small molecules like Nicoclonate are designed to bind to specific proteins or receptors in the body, which can help to regulate various physiological processes. This binding can either activate or inhibit the target, leading to a therapeutic effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nicoclonol CI brief — competitive landscape report
Nicoclonol updates RSS · CI watch RSS

Frequently asked questions about Nicoclonol

What is Nicoclonol?

Nicoclonol (NICOCLONATE) is a nicoclonate drug.

How does Nicoclonol work?

Nicoclonate is a small molecule that works by interacting with a specific target in the body, but the exact mechanism is unknown.

What is the generic name of Nicoclonol?

NICOCLONATE is the generic (nonproprietary) name of Nicoclonol.

What drug class is Nicoclonol in?

Nicoclonol belongs to the nicoclonate class. See all nicoclonate drugs at /class/nicoclonate.

What development phase is Nicoclonol in?

Nicoclonol is in Phase 2.

Drug class: All nicoclonate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing